Endpoints News
Post-Hoc Live
Post-Hoc Live is an extension of Endpoints' analysis newsletter Post-Hoc — but streamed live on YouTube then brought to you here. Our reporters spend every day texting and calling sources, reading executive orders, and talking to each other in Slack. We're bringing that analysis that happens behind the scenes directly to you, and letting you in on some of our up-to-the-moment conversations. Subscribe to Endpoints and the Post-Hoc newsletter here: https://profile.endpoints.news/create-account. Send us an email at: posthoclive@endpointsnews.com
No dejes de visitar la web del podcast y apoyar a su creador: podcasters.spotify.com
Autor
Endpoints News
Categoría
Web del podcast
Último episodio
4 de nov. de 2026
¿Dónde escuchar?
Podcasts en la app Replaio Radio Muy prontoLos podcasts llegarán muy pronto a la app. Instálala ahora y sé el primero en descubrir una forma totalmente nueva de vivir los podcasts
Episodios
The US midterm elections and biopharma 04.11.2026 43:07
The results of the midterm elections could swing control of Congress — with a range of potential impacts for biopharma, from the US posture towards China to drug pricing. After the results are called, we’ll be live with regular guest and DC politics and policy expert Nick Shipley talking about what the vote means for the biotech and pharma industry. Stay ahead of biopharma. Get the Main Edition in...
Is biotech’s future full of zero-employee startups? 30.10.2026 39:22
Anthropic announced this week that it had acquired Mithril Medicine, a one-person biotech. It’s an early test of the idea that, with heavy use of AI and contracts with external labs, a biotech could run without much (or any) human guidance. We’ll talk about how one- and no- employee companies are getting built and what they mean for the future of biopharma. Stay ahead of biopharma. Get the Main Ed...
Did Treasury’s COINS rule just end China biotech deals? 23.10.2026 41:41
For weeks, biotech and pharma have been waiting for the Treasury Department’s proposed rule on the COINS Act and how it would affect the industry. Thursday’s announcement was a surprise: a broad set of drug technologies made the list of prohibited China investments by US entities. Will the rule kill off the US drug industry’s partnering with China biotech, which has led to scores of deals in 2025...
Live from DC: Will Congress put a stop to China biotech deals? 17.09.2026 24:27
There isn't a lawmaker on Capitol Hill who's publicly taken a more conservative stance to biopharma's deal spree in China than Rep. John Moolenaar (R-MI), chairman of the House Select Committee on China. He's been the architect of recent legislative proposals that'd clamp down on deals there and also what data regulators can review. So how did this issue rise to his attention?...
Live from DC: Is secrecy the solution? 17.09.2026 26:30
What do you do when you announce a drug program, then turn around and find out that there are a dozen competitors in China working on the same idea? For many US biotechs, the answer has been to hide their work as long as possible, limiting what they share with the outside world in the hope that it will keep new competitors from emerging (and passing them by). It's a tactic that's been adop...
Live from DC: What do we really mean when we talk about biosecurity risk and China? 17.09.2026 26:08
Huge genetic databases. Drug ingredient supply chains. A next pandemic. War with Taiwan. Economic competition. A huge number of topics and scenarios get lumped into the "China biosecurity" conversation — some present and real, some far-fetched and far-off. So what are we really talking about when we talk about China and bio-risk? What deserves the attention and policy action? Which ones...
Live from DC: Can the FDA steer clinical trials back to the US? 17.09.2026 23:17
If investment restrictions are the potential consequences to a drug industry that's looked overseas for new assets and early trials, then what's the incentive to come back? The FDA is working to figure it out, and a new agency pilot program is meant to reinvigorate early human research in the US. But is it enough? And is the FDA moving with the urgency that many in the industry say is requ...
Live from Boston: How pharma thinks about China 07.08.2026 24:04
As large pharma companies increasingly turn to China to fill their pipelines, what long-term affect will it have on their strategy and operations? Pfizer's Andrew Baum shares the large drugmaker perspective on acquisitions, R&D, and how the industry could change in the years to come. Live from Endpoints’ China Biotech Debate: Boston on August 6, 2026.
Live from Boston: Investor math versus industrial priority 07.08.2026 45:10
Should investors embrace China’s fast-moving, fast-growing biotech sector, or should there be barriers to protect and preserve an industry that the US has dominated for decades? Ginkgo Bioworks CEO Jason Kelly, RA Capital Management's Peter Kolchinsky, and MIT professor Fiona Murray debate all sides of the flashpoint issue. Live from Endpoints’ China Biotech Debate: Boston on August 6, 2026.
Live from Boston: Has China changed how we build companies? 07.08.2026 27:25
In a world where promising drugs are quickly copied, improved on and raced into trials, is science still a differentiator? Strand Therapeutics CEO Jake Becraft and Roivant Sciences CEO Matt Gline discussed what actually counts as innovation, and if where the innovation happens matters for how the industry brings programs to patients. Live from Endpoints’ China Biotech Debate: Boston on August 6, 2...
The case for — and against — an AZ-BMS megadeal 04.08.2026 35:10
AstraZeneca and Bristol Myers Squibb are reportedly in talks to combine, which would be one of the largest mergers the biopharma industry has ever seen. What could each company get out of the deal, and what would this deal mean for the industry overall? And are megamergers back? Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D
Record IPOs — with Parabilis and Kailera’s CEOs 16.07.2026 33:54
Kailera broke records with its $625 million IPO in April. But its high-water mark didn’t last long — in June, Parabalis made a $670 million debut, putting its own name on top of the record books. On Post-Hoc Live, we’re joined by Ron Renaud and Mathai Mammen, the CEOs of the companies, to talk about what it took to reach those heights. Stay ahead of biopharma. Get the Main Edition in your inbox M...
Are the China hawks winning? 22.06.2026 42:22
WuXi is back on the Pentagon’s blacklist. The United States Treasury might restrict investments in Chinese biotech. Despite wave after wave of big pharma announcements around partnerships with China, the protectionist voices are taking up more airtime. Where are the winds blowing, and what material impact could this all have? Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30...
How much is everyone in biopharma getting paid? 09.06.2026 32:38
CEO pay keeps going up, and up, and up. What do the pay ratios at pharmas say about the state of the industry as a whole, and how do the eye-popping numbers affect global competition? On Post-Hoc Live, we’ll take you behind the scenes of Endpoints’ annual biopharma compensation report, which breaks down pay for top execs and median workers. Stay ahead of biopharma. Get the Main Edition in your in...
How to stabilize US biotech — with Dr. Jeremy Levin 27.05.2026 32:56
Jeremy Levin has seen the biopharma industry from practically every vantage point. Now, with decades of experience under his belt, he’s out front in the chorus of veterans sounding the alarm about threats to US dominance in biotech. He joins Post-Hoc Live to talk about China, US policy, and how to stem the bleeding. Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. S...
Makary's out: Live from the FT Summit 15.05.2026 29:01
Marty Makary resigned as FDA commissioner on Tuesday after a turbulent tenure at the head of the agency. The Endpoints and Financial Times teams sat down at the US Pharma and Biotech Summit on Thursday to talk about his tenure, his downfall, and where the FDA goes from here. Stay ahead of biopharma. Get the Main Edition in your inbox M-F at 11:30 AM ET. Sign up: https://shorturl.at/OBB3D
Q1 earnings recap with Endpoints News 12.05.2026 38:18
Thanks to our premium subscribers who joined us live for this special episode of Post-Hoc Live. Catch up on the recording now:Are more deals coming, after a deal-heavy Q1? How are IRA negotiations and MFN deals affecting outlooks? What's the state of the oral weight loss race between Novo and Lilly? We’ll dig into key results and predict what they could mean for the rest of the year.
Trust, MAHA, and what’s next for the CDC 24.04.2026 34:15
The CDC hasn’t had a Senate-confirmed director since August. But last week, President Trump announced his next pick — Erica Schwartz, a former deputy surgeon general. She’s a more traditional public-health choice, and if confirmed, faces the formidable tasks of stabilizing the agency and working with RFK Jr., whose anti-vax and MAHA allies have already criticized the pick. We’re joined by Brinda A...
The spring deals bonanza 10.04.2026 36:39
Pharma companies went on a dealmaking spree over the past few weeks, signing acquisitions worth up to $25.5B in two weeks in March alone. It’s shaping up to be a big year — if the pace continues. We’re joined by Emily Field, head of US biopharmaceuticals equity research at Barclays, to break down the factors contributing to the deal flow and make predictions for the rest of the year. Stay ahead o...
The politics of vaccines — with former congressman Dr. Michael Burgess 31.03.2026 35:11
With the midterms looming, Trump’s HHS seems to be backing off vaccines and pivoting toward healthy eating — playing up the aspects of RFK Jr.’s agenda that are popular, rather than those that cater to his base. Is the new focus working, and will it last? We’re joined by former US Representative Dr. Michael Burgess to talk through the political landscape around vaccines and why he thinks it’s a li...
Who won the Hims vs Novo feud? 10.03.2026 28:24
Hims and Novo seem to have made up. After the fraught few days last month when Hims announced a compounded version of Novo’s weight loss pill, Novo sued, and regulators threatened investigations, the two companies came to a deal: Hims & Hers will sell the name-brand drugs and limit sales of compounded meds. Now that the dust has started to settle, who came out on top, what does the deal mean f...
Protecting US biotech from Chinese competition — with the NSCEB 06.03.2026 36:06
Last week, the U.S. International Trade Commission said it would investigate whether US biotech companies were at an unfair disadvantage because of Chinese pricing practices. The move was one of the many recommendations made by the National Security Commission on Emerging Biotechnology, which has spent the past year taking a close look at the rise of China’s biotech industry. Friday on the show, E...
Moderna vs the FDA 11.02.2026 30:03
The biotech and pharma industry might be reaching breaking point with the FDA. Moderna said on Tuesday that the agency won’t review its mRNA-based flu vaccine — and through unusually public disclosures, accused the FDA of changing agreed-upon standards for its trial. And in responses to Endpoints’ Q1 Biopharma Sentiment Index, industry insiders unloaded their frustrations and fury with US official...
Hims, Novo, and a new front in the compounding wars 06.02.2026 32:17
It’s only been a month since the FDA signed off on Novo Nordisk’s pill version of its weight-loss drug Wegovy, and the telehealth company Hims & Hers already says it’s going to sell a cheaper, compounded version of the pills. Novo is not happy — to say the least. Today on the show, we’ll dig into this new front in the compounding wars.
Post-Hoc Live, Live! at #JPM26 with Noubar Afeyan 20.01.2026 27:09
How existential are the current threats to US science? Noubar Afeyan, founder and CEO at Flagship Pioneering, joined us to point out the various landmines dotting the landscape during a live taping of Post-Hoc Live out at the JP Morgan Healthcare Conference.
Podcasts similares
Replaio no es editor de podcasts; los nombres de los programas, las portadas y el audio pertenecen a sus autores y se distribuyen a través de canales RSS públicos